A tragic paradox, Gilead updates and a lot of new pfizer

Adam Feuerstein / Stat

Matthew Herper covers medical innovation – both his promise and his perils.

Adam Feuerstein is a main writer and biotechnology columnist, reporting on the crossroads of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotech podcast The Readout Loud and author of the Biotech dashboard of the Adam newsletter. You can reach Adam on the signal to stataf.54.

Angus Chen covers all questions largely linked to cancer, including drugs, policies, science and equity. He joined Stat in 2021 after covering health and science in the NPR and NPR affiliation stations. His work was recognized by the National Edward R. Murrow Awards, June L. Biedler Prize for cancer journalism, and even more. You can reach Angus on the signal in Angus.08.

This is the web version of the STAT newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest cancer news, register for our briefing newsletter on cancer here.

Asco is generally suffocating, but it is surprisingly cold today. We are back with an overview of tragic paradoxes, a breed for new drugs against breast cancer and all this jazz.

First of all, we would like to thank everyone who turned out for our Stat @ Asco event last night. It was a crowded house and a large crowd. A reminder: our summary event of virtual statistics on the conference will be on Wednesday, and it is not too late to register.

Stat + Exclusive History

Stat +

This article is exclusive to stat + subscribers

Unlock this article – plus daily coverage and analysis of the biotechnological sector – in SUT +subscription.

Do you already have an account? Connect

Show all plans

To read the rest of this story, subscribe to Stat +.

Get down

Principal writer, medicine, editorial director of events
Matthew Herper covers medical innovation – both his promise and his perils.
Adam Feuerstein is a main writer and biotechnology columnist, reporting on the crossroads of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotech podcast The Readout Loud and author of the Biotech dashboard of the Adam newsletter. You can reach Adam on the signal to stataf.54.
Angus Chen covers all questions largely linked to cancer, including drugs, policies, science and equity. He joined Stat in 2021 after covering health and science in the NPR and NPR affiliation stations. His work was recognized by the National Edward R. Murrow Awards, June L. Biedler Prize for cancer journalism, and even more. You can reach Angus on the signal in Angus.08.